159 related articles for article (PubMed ID: 27034745)
1. Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease.
Bartnicki P; Rysz J; Franczyk B; Baj Z; Majewska E
Oxid Med Cell Longev; 2016; 2016():9879615. PubMed ID: 27034745
[TBL] [Abstract][Full Text] [Related]
2. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
[TBL] [Abstract][Full Text] [Related]
3. Influence of continuous erythropoietin receptor activator on markers of cardiovascular risk in chronic kidney disease patients.
Noce A; Dessì M; Durante O; Manca di Villahermosa S; Canale MP; Di Daniele N
Int J Cardiol; 2013 Sep; 167(6):3070-2. PubMed ID: 23218579
[No Abstract] [Full Text] [Related]
4. Early markers of cardiovascular risk in chronic kidney disease.
Lai S; Dimko M; Galani A; Coppola B; Innico G; Frassetti N; Mazzei ED; Mariotti A
Ren Fail; 2015 Mar; 37(2):254-61. PubMed ID: 25394527
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
Bartnicki P; Kowalczyk M; Franczyk-Skóra B; Baj Z; Rysz J
Curr Vasc Pharmacol; 2016; 14(4):360-7. PubMed ID: 26759218
[TBL] [Abstract][Full Text] [Related]
6. Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study.
Ino J; Kasama E; Kodama M; Harada T; Sato K; Eizumi H; Kawashima Y; Nitta K
Clin Exp Nephrol; 2020 Jul; 24(7):590-597. PubMed ID: 32185544
[TBL] [Abstract][Full Text] [Related]
7. Endocan--the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease.
Pawlak K; Mysliwiec M; Pawlak D
Clin Biochem; 2015 Apr; 48(6):425-30. PubMed ID: 25617664
[TBL] [Abstract][Full Text] [Related]
8. Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
Gennip ACEV; Broers NJH; Meulen KJT; Canaud B; Christiaans MHL; Cornelis T; Gelens MACJ; Hermans MMH; Konings CJAM; Net JBV; Sande FMV; Schalkwijk CG; Stifft F; Wirtz JJJM; Kooman JP; Martens RJH
PLoS One; 2019; 14(9):e0222547. PubMed ID: 31518378
[TBL] [Abstract][Full Text] [Related]
9. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.
von Scholten BJ; Reinhard H; Hansen TW; Schalkwijk CG; Stehouwer C; Parving HH; Jacobsen PK; Rossing P
J Diabetes Complications; 2016 Mar; 30(2):248-55. PubMed ID: 26651261
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia.
Locatelli F; Mandolfo S; Menegato Adorati M; Villa G; Tarchini R; Pizzarelli F; Conte F; Guastoni C; Ricciardi B; Crotta A
J Nephrol; 2013; 26(6):1114-21. PubMed ID: 24052462
[TBL] [Abstract][Full Text] [Related]
11. Independent Echocardiographic Markers of Cardiovascular Involvement in Chronic Kidney Disease: The Value of Left Atrial Function and Volume.
Kadappu KK; Abhayaratna K; Boyd A; French JK; Xuan W; Abhayaratna W; Thomas L
J Am Soc Echocardiogr; 2016 Apr; 29(4):359-67. PubMed ID: 26743735
[TBL] [Abstract][Full Text] [Related]
12. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
Musiał K; Zwolińska D
Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
[TBL] [Abstract][Full Text] [Related]
13. Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease.
Chen J; Hamm LL; Mohler ER; Hudaihed A; Arora R; Chen CS; Liu Y; Browne G; Mills KT; Kleinpeter MA; Simon EE; Rifai N; Klag MJ; He J
PLoS One; 2015; 10(7):e0132047. PubMed ID: 26132137
[TBL] [Abstract][Full Text] [Related]
14. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
15. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.
Hassan SB; El-demery AB; Ahmed AI; Abukhalil RE
Arab J Nephrol Transplant; 2012 Jan; 5(1):27-32. PubMed ID: 22283863
[TBL] [Abstract][Full Text] [Related]
16. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
[TBL] [Abstract][Full Text] [Related]
17. Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats.
Serizawa K; Yogo K; Tashiro Y; Aizawa K; Kawasaki R; Hirata M; Endo K
Eur J Pharmacol; 2015 Nov; 767():10-6. PubMed ID: 26432688
[TBL] [Abstract][Full Text] [Related]
18. Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study.
Gupta J; Dominic EA; Fink JC; Ojo AO; Barrows IR; Reilly MP; Townsend RR; Joffe MM; Rosas SE; Wolman M; Patel SS; Keane MG; Feldman HI; Kusek JW; Raj DS;
PLoS One; 2015; 10(4):e0124772. PubMed ID: 25909952
[TBL] [Abstract][Full Text] [Related]
19. Serum uric acid independently predicts cardiovascular events in advanced nephropathy.
Kanbay M; Yilmaz MI; Sonmez A; Solak Y; Saglam M; Cakir E; Unal HU; Arslan E; Verim S; Madero M; Caglar K; Oguz Y; McFann K; Johnson RJ
Am J Nephrol; 2012; 36(4):324-31. PubMed ID: 23007099
[TBL] [Abstract][Full Text] [Related]
20. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease.
Goicoechea M; Quiroga B; García de Vinuesa S; Verdalles U; Reque J; Panizo N; Arroyo D; Santos A; Macías N; Luño J
Ren Fail; 2012; 34(8):1002-9. PubMed ID: 22746155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
